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Summary Vascular endothelial growth factor (VEGF) expression and mutations of cancer-related genes increase with cancer progression.
This correlation suggests the hypothesis that oncogenes and tumour suppressors regulate VEGF, and a significant correlation between p53
alteration and increased VEGF expression in human lung cancer was reported recently. To further examine this hypothesis, we analysed
VEGF protein expression and mutations in p53 and K-ras in 27 non-small-cell lung cancers (NSCLC): 16 squamous cell, six
adenocarcinomas, one large cell, two carcinoids and two undifferentiated tumours. VEGF was expressed in 50% of the squamous cell
carcinomas (SCC) and carcinoids but none of the others. p53 mutations occurred in 14 tumours (52%), and K-ras mutations were found in two
adenocarcinomas and one SCC; there was no correlation between the mutations and VEGF expression. As nitric oxide also regulates
angiogenesis, we examined NOS expression in NSCLC. The Ca2+-dependent NOS activity, which indicates NOS1 and NOS3 expression,
was significantly reduced in lung carcinomas compared with adjacent non-tumour tissue (P < 0.004). Although the Ca2+-independent NOS
activity, which indicates NOS2 expression, was low or undetectable in non-tumour tissues and most carcinomas, significant activity occurred
in three SCC. In summary, our data do not show a direct regulation of VEGF by p53 in NSCLC. Finally, we did not find the up-regulation of
NOS isoforms during NSCLC progression that has been suggested for gynaecological and breast cancers.
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Tumours cannot exceed 1-2 mm3 volume without developing new
blood vessels (Folkman, 1990). Therefore, solid tumours must
produce angiogenic factors, such as vascular endothelial growth
factor (VEGF), at an early point in development (Hanahan and
Folkman, 1996). VEGF expression is critical in tumour models
(Kim et al, 1993; Millauer et al, 1994). VEGF overexpression
occurs in human cancers of the lung (Mattem et al, 1995), colon
(Brown et al, 1993) and brain (Plate et al, 1994), and has been
found to correlate with nuclear accumulation ofp53 in human lung
and colon cancer (Fontanini et al, 1997a; Kang et al, 1997) and
poor prognosis in NSCLC (Mattern et al, 1995; Fontanini et al,
1997b). VEGF expression is induced by hypoxia (Shweiki et al,
1992; Forsythe et al, 1996), and a mutationally activated ras onco-
gene (Rak et al, 1995; Larcher et al, 1996; Mazure et al, 1996) or
p53 (Kieser et al, 1994) acts synergistically with hypoxia to induce
VEGF expression. In contrast, wild-type p53 down-regulates
VEGF promoter activity (Mukhopadhyay et al, 1995) and up-
regulates the expression of the antiangiogenic factor thrombo-
spondin-1 (Dameron et al, 1994). These observations suggest that
oncogenes and tumour-suppressor genes regulate angiogenesis.
However, p53 alterations did not correlate with VEGF expression
in brain cancers (Plate et al, 1994) and, in a recent report,
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wild-type p53 did not repress hypoxia-induced transcription of
VEGF (Agani et al, 1997).
Hypoxia stimulates both VEGF and NOS2 expression, the latter
in collaboration with cytokines (Melillo et al, 1995). Nitric oxide
mediates tumour vascularization and growth (Maeda et al, 1994;
Jenkins et al, 1995; Thomsen et al, 1997); tumour blood flow
(Tozer et al, 1997) and VEGF-stimulated proliferation ofcoronary
endothelial cells depend on NOS activity (Ziche et al, 1997).
Combating tumour angiogenesis (Harris, 1997) is a promising
therapeutic strategy that may target expression ofVEGF, NOS and
other components ofthe angiogenesis pathway. Hence, we charac-
terized the expression ofVEGF and NOS in 27 NSCLC in relation
to p53 and K-ras mutations. Although there are no correlations
between those factors in NSCLC, we did find a statistically signif-
icant reduction in Ca2+-dependent NOS activity (NOS1 and -3) in
tumour vs non-tumour tissue and a marked NOS2 expression in
three squamous cell carcinomas.
MATERIALS AND METHODS
Materials
A1-monomethyl-L-arginine (L-NMA), flavin adenine dinucleotide
(FAD) and (6R,S)-5,6,7,8-tetrahydro-L-biopterin (BH4) were
purchased from Calbiochem (San Diego, CA, USA); the Dowex AG
50W-X8 resin, 200-400 mesh, sodium form, from Bio-Rad
(Richmond, CA, USA), and the BCA protein reagent from Pierce
(Rockford, IL, USA); rabbit polyclonal anti-NOS2 antibodies were
either purchased from Transduction Laboratories (Lexington, KY,
USA) or kindly provided by Merck (Rahway, NJ, USA); the rabbit
polyclonal anti-VEGF (A-20) antibody was purchased from Santa
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Table 1 Summary of VEGF and p53 immunohistochemistry, NOS2 activity and mutations of the p53 and K-ras genes in lung cancer
Tumour p53 Base K-ras
Case type Stage NOS2 VEGF IHC p53 IHC mutation WT Seq. MUT Seq. change Smoking mutationa
1 scC II 36.5 2 3 None No record
2 SCC 0 2 3 None Yes, D/C 30
3 CAR IV 0 2 0 None No record
4 SCC 0.3 2 1 None 30 GGT > TGT
5 SCC 1.7 1 2 216 GTG ATG G > A 120, D/C 5
6 SCC 1.3 1 2 157 GTC TTC G > T 50
7 scC 0.5 1 1 195 ATC ACC T > C Non-smoker
8 SCC II 1.3 1 0 258 GAA TAA G > T > 20
9 SCC 1.1 1 0 None No record
10 SCC 162 0 3 286 GAA AAA G > A 25, D/C 34
11 NSCLC 3 0 3 173 GTG TTG G > T 40
12 SCC II 1.4 0 3 163 TAC TGC A>G No record
13 LCLC 0.2 0 3 245 GGC AGC G > A 50, D/C 14
14 AD III 0 0 3 278 CCT CTT C > T No record
15 SCC II 11.3 0 2 272 GTG TTG G > T 10
16 AD II 0 0 2 None 108
17 SCC 0 0 2 248 CGG TGG C > T 13
18 SCC 0 0 2 282 CGG TGG C > T No record
19 SCC 0.8 0 1 65-73 Del 21bp No record
20 CAR 3.3 0 0 None 100, D/C 3
21 SCC II 1.9 0 0 158 CGC CTC G > T 45, D/C 15
22 AD 1.5 0 0 None 50
23 AD III 0 0 0 None 30
24 SCC 0 0 0 None 120
25 AD III 0 0 0 None Yes GGT > GTT
26 AD 0 0 0 None 50, D/C 6 GGT > TGT
27 NSCLC 0 0 0 None No record
SCC, squamous cell carcinoma; AD, adenocarcinoma; CAR, carcinoid; NSCLC, non-small-cell lung carcinoma; LCLC, large-cell lung carcinoma. WT/MUT Seq,
wild-type/mutated sequence; DEL, deletion. VEGF and p53 immunohistochemistry (IHC): 0, none; 1, few cells/small foci; 2, < 10-70%; 3, > 70%. Smoking unit:
pack-years, one pack of cigarettes per day per year; D/C, discontinued. NOS2 activity in pmol min-' mg-' protein. aAll at codon 12.
Cruz Biotechnology (SantaCruz, CA, USA); the mouse monoclonal
anti-p53 antibody DO-7 was from Oncogene Research Products
(Cambridge, MA, USA). T7 Sequenase 7-deaza sequencing kit, oc-
(35S)-dNTPs and L-(2,3,4,5-3H)-arginine were obtained from
Amersham (Arlington Heights, IL, USA). Taq-polymerase was
received from Perkin Elmer/Roche (Blanchburg, NJ). Primers were
prepared with a Beckman Oligo 1000 DNA synthesizer (Palo Alto,
CA, USA).
Tissue collection and preparation of soluble tissue
extracts
With the approval of local boards governing research on human
subjects, surgically resected frozen lung (n = 27) and surrounding
non-tumour tissues were obtained from either the Cooperative
Human Tissue Network (Birmingham, AL, USA; Columbus, OH,
USA; Philadelphia, PA, USA) or the University of Maryland,
Department of Pathology (Baltimore, MD, USA), and stored at
- 70°C. Tobacco histories were obtained from medical charts
(CHTN) or case-control epidemiological study questionnaire
(UMD). Tissue fragments (< 500 mg) were crushed with a pestle
and mortar under liquid nitrogen and homogenized with a
PowerGen 125 homogenizer in 1.5-2.5 ml of buffer A [50 mM
HEPES, 1 mMdithiothreitol(DTT), 1 mML-citrulline, 1 mmmagne-
sium chloride, 5 mg 1-1 pepstatin A, 0.1 mmphenylmethylsulphonyl
fluoride (PMSF), 3 mg 1-1 aprotinin, pH 7.4] at 0-4°C. Endogenous
arginine was removed by addition of Dowex AG 50W-X8 resin
(approx. 200 mg). The samples were centrifuged (O5 000g, 4°C,
10 min) and the supernatants were used for determination of NOS
activity. Protein was determined with the BCA protein reagent at
562 nm using bovine serum albumin (BSA) as a standard.
Assay of NOS activity
The conversion ofL-arginine to L-citrulline was measured using a
modification of a described method (Salter et al, 1991). The assay
was started by addition of 100pl of tissue extract to 100 ,1 of
assay buffer (buffer A containing 100 gM arginine, 100 000 d.p.m.
L-(2,3,4,5-3H)-arginine, 2 mM NADPH, 5 ,UM BH4, 5 gM FAD and
0.5 mmcalcium chloride for determination oftotal NOS activity or
1 mm EGTA to determine the Ca2+-independent NOS activity). In
order to determine L-arginine metabolism due to NOS, each
sample was assayed ± 1 mm L-NMA. After 30 min at 37°C, the
enzymatic reaction was stopped with 100pl of 1 M trichloroacetic
acid (TCA). The samples were adjusted to pH 4.6 by addition of
500 gl of 200 mM HEPES, pH 8, and loaded on Dowex AG 5OW-
X8 resin columns. The columns were washed with 300,1 of
50 mM HEPES, 1 mM L-citrulline and 1 mM EGTA, pH 7.4. The
eluates were counted. The L-NMA sensitive L-arginine to L-
citrulline conversion was used forcalculation ofenzyme activities.
Histological review of tissues, and VEGF, NOS2 and
p53 immunohistochemical staining
Portions of frozen tissue samples were fixed in 100% ethanol and
embedded in paraffin. Haematoxylin and eosin-stained sections of
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Figure 1 Immunostaining for VEGF in human lung carcinoma. Lung sections were stained with a polyclonal anti-VEGF antibody and a brown chromogen,
diaminobenzidine. Cytoplasmic VEGF is shown in epithelial cells of three squamous cell carcinomas (A-C) and an atypical carcinoid carcinoma (D);
magnification is x 100 for A and C; x 630 for B and D. Counterstain is methyl green for A and B, and haematoxylin for C and D
tumour and non-tumour tissues were reviewed for tumour content
and inflammatory infiltrate. Immunohistochemistry was performed
by deparaffinizing and rehydrating unstained 5-micron sections.
Endogenous peroxidase activity was blockedby treatment with 0.3%
hydrogen peroxide in Dulbecco's phosphate-buffered saline (DPBS)
for 20 min at room temperature. Sections were incubated at 8-10°C
for 20 min in a humidified chamber with a 1:50 dilution of normal
goat serum in PBS/2% BSA. After washing with PBS, sections were
incubated with a polyclonal rabbit anti-NOS2 antibody either from
Transduction Laboratories, diluted 1:100, or from Merck, diluted
1:10 000, or with a polyclonal rabbit anti-VEGF antibody (Santa
Cruz Biotechnology), 1:400 dilution, or with a monoclonal mouse
anti-p53 antibody (Oncogene Research Products), 1:50 dilution, in
PBS/2% BSA for 45 min. Slides were then rinsed with PBS and
incubated with a secondary, biotin-labelled antiserum, either goat
anti-rabbit or horse anti-mouse Ig antibody (Vectastain, ABC Elite
Kit, Vector Laboratories, Burlingame, CA, USA). After incubation
with an avidin-biotin-peroxidase complex, slides were stained with
3,3-diaminobenzidine for 20 min. Controls included sections stained
with the second antibody only or with a control IgG substituted for
the primary antibody (used for NOS2).
Western blot analysis
Protein extracts were prepared from tissue pieces crushed under
liquid nitrogen and homogenized on ice in RIPA buffer [50 mM
Tris-HCl, pH 7.4, 150 mm sodium chloride, 1% Triton X-100, 1%
deoxycholate, 0.1% sodium dodecyl sulphate (SDS)] containing
1 mm DTT, 0.1 mm PMSF, 1 mm vanadate and 10 mg 1-' aprotinin.
Supematant was prepared by centrifugation at 120 000g for
10 min, and protein concentrations were determined with the BSA
protein reagent. For NOS2, 300 ,ug of soluble protein extract was
loaded on a SDS/7% polyacrylamide gel and was separated at
150 V for 2 h. VEGF expression was determined by IP-Western.
Then, 5 gg of rabbit polyclonal anti-VEGF antibody (Santa Cruz
Biotechnology) was added to 1 mg of protein extract and
incubated for 1 h at 8-10°C; 10 mg of protein A-sepharose
(Pharmacia, Piscataway, NJ, USA) was added, mixed for 1 h at
room temperature and the samples were spun at 10 000 g. The
pellet was washed with RIPA buffer, heated at 950C (+ 5 x SDS/
DTT loading buffer, 5,3-Prime, Boulder, CO, USA) and the
VEGF-containing supematant was loaded on a 13% gel. After
electrophoretical transfer to an Immobilon-P membrane
(Millipore, Bedford, MA, USA), unspecific binding was blocked
by incubation in TBST (10 mm Tris, pH 8, 100 mM sodium chlo-
ride, 0.05% Tween 20) + 4% BSA for 4 h at room temperature.
The membranes were probed either with a polyclonal anti-human
NOS2 antibody (Merck), diluted 1:40 000 in TBST, or with rabbit
polyclonal anti-VEGF antibody, diluted 1:1000 in TBST/2% BSA.
After washing 3 x in TBST, the membrane was probed with an
anti-rabbit Ig peroxidase-coupled antibody (Amersham) diluted
1:10 000 in TBST/2% BSA. Blots were developed using the
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Renaissance Western blot chemiluminescence system (Du Pont,
Boston, MA, USA) and exposed to Hyperfilm-ECL (Amersham).
Sequence analysis of the p53 and K-ras genes
Paraffin-embedded tumour samples were dewaxed and micro-
dissected from 50-gm sections. Genomic DNA was isolated by
SDS/proteinase K treatment (final concentration, 1% SDS and
0.5 mg ml-' of proteinase K) at 50°C for 24-48 h, followed by
phenol-chloroform extraction, ethanol precipitation and resuspen-
sion in 50 ,ul ofsterile water. The most common mutated p53 coding
sequence from exons 4-10 was amplified (58°C, 1 min; 72°C,
0.5 min; 94°C, 1 min) and sequenced with the T7 sequenase kit
(Amersham) using amplification and sequencing conditions as
described by Lehman et al (1991). For purification before
sequencing, the polymerase chain reaction (PCR) products were
loaded on a 4% agarose gel (3:1 NuSieve) and separated from left-
over primers by electrophoresis at 50 V for 2 h. K-ras was amplified
and sequenced as described (Lehman et al, 1991) with the following
two primer pairs, consisting ofan external primerpair for first-round
PCR and an internal primer pair for a second-round PCR and
sequencing: external primer pair, 5'-primer GTACTGGTGGAG-
TATlllGAT, 3'-primer GAGACTGGTAAAAGTACTCA; internal
primer pair, 5'-primer ACATGTTCTAATATAGTCAC, 3'-primer
GACCACGTCCTGGTAAGAAA.
Statistical analysis
Comparisons between two characteristics were carried out using
the Mann-Whitney U rank-sum test. Relationships were consid-
ered statistically significant when P < 0.05.
RESULTS
VEGF expression
Positive staining for VEGF was obtained in 8 out of 16 SCC
(50%). VEGF was expressed in the cytosol of tumour epithelial
cells (Figure 1A-D) and was focally distributed in most cases.
VEGF expression was also observed in one atypical carcinoid
tumour (Figure 1D) but not in six adenocarcinomas, one carcinoid,
one large-cell carcinoma or two undifferentiated NSCLCs (Table
1). The specificity of VEGF immunohistochemistry (IHC) was
verified by Western blot analysis with the detection of expected
VEGF protein bands at 24-28 kDa (Figure 5) in extracts of
NSCLCs, which showed intensive VEGF immunostaining. VEGF
protein bands were not detected in NSCLCs, which were negative
for VEGF by IHC (data not shown).
p53 and K-ras mutations, and the relation to VEGF
p53 mutations were detected in 14 cases (52%). One SCC had a
2l-bp deletion mutation in exon 4, while all other mutations were
missense mutations in exons 5-8 (Table 1). G > T transversions (5
out of 14, 36%) were the most common mutations. p53 gene muta-
tions and nuclear p53 protein accumulation correlated strongly
(P < 0.01). Two adenocarcinomas and one SCC carried K-ras
mutations at codon 12 (Table 1). Out of eight SCC that expressed
VEGF, five had aberrant p53 function indicated by nuclear p53
protein accumulation or mutation analysis, while one other tumour
carried a K-ras mutation (Table 1). In comparison, seven out of
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Figure 2 Ca2+-dependent NOS activity in human lung cancer. The activity
was determined as the L-NMA-sensitive conversion of arginine to citrulline.
Ca2+-dependent NOS activity is significantly decreased in lung carcinoma
compared with the activity in the surrounding normal tissue (both n = 27)
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Figure 3 Ca2+-independent NOS activity in lung. NOS activity was
measured as the L-NMA-sensitive conversion of arginine to citrulline,
+ 0.5 mM EGTA. Although Ca2+-independent NOS activity was mainly low or
undetectable in lung and did not differ significantly between carcinomas (CA)
and normal tissue (N), a marked activity was present in three carcinomas
eight SCC without detectable VEGF expression carried a p53
mutation as shown by mutation analysis (Table 1). Hence, the
frequency of p53 inactivation, judged by nuclear protein accumu-
lation in tumour cells or the presence of a mutation, was lower in
SCC with VEGFexpression (63%) than in SCC without detectable
VEGF expression (88%). The combined frequency of p53/K-ras
alterations was 75% in VEGF-positive SCC and 88% in VEGF-
negative SCC. Thus, there was no association between VEGF
expression in SCC and an apparent loss of p53 function and/or
activation of K-ras.
NOS activity and NOS2 expression in lung tissues
Ca2+-dependent NOS activity, suggesting the presence of the
neuronal (NOS1) and/or endothelial (NOS3) isoforms, was
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Figure 4 NOS2 immunostaining in lung carcinoma. Lung sections were
stained with a polyclonal anti-NOS2 antibody and a brown chromogen,
diaminobenzidine. NOS2 protein was detected in both tumour-infiltrating
monocytes (A, x 630) and in the tumour epithelium (B, x 630). Methyl green
counterstain. Both carcinomas contained high Ca2+-independent NOS activity
significantly reduced in tumour tissue compared with normal
lung tissue (both n = 27, P < 0.004) (Figure 2). Although Ca2+-
independent NOS activity was mainly low or undetectable in lung
tissues and did not differ significantly between carcinomas and
normal tissue (P = 0.15), high activities were found in three SCC
(Figure 3).
Since Ca2+-independent NOS activity denotes NOS2 expres-
sion, we used IHC to determine the distribution of NOS2 protein.
In the three tumours with high Ca2+-independent NOS activity,
NOS2 was detected in tumour-infiltrating monocytes (Figure 4A).
NOS2 was also present in the tumour endothelium of two tumours
and in the tumour epithelium of one SCC (Figure 4B). The expres-
sion of NOS2 was focal in all cases. We buttressed these observa-
tions with the detection of the specific 130-kDa NOS2 protein
band by Western blot analysis. Using the protein extract of carci-
noma no. 1 (see Table 1), which was positive for both NOS2 and
VEGF by IHC, we obtained the 130-kDa band of NOS2 (Figure
5). The protein expression data support the observation of NOS2
activity within these tumours.
DISCUSSION
The expression of VEGF correlates temporally with the onset of
mutations in cancer-related genes, and mutations in both ras (Rak
Figure 5 Detection of NOS2 and VEGF protein by Western blot analysis.
Protein extracts from SCC no. 1 (T) and the surrounding normal tissue (N)
were analysed. Protein bands were obtained at 130 kDa for NOS2 (A) and a
double band at 26-28 kDa for VEGF (B). In agreement with the IHC
analysis, only the carcinoma contains detectable amounts of NOS2 and
VEGF protein. For NOS2, 300 ,ug of protein extract were separated on a 7%
polyacrylamide gel. For VEGF, 5 1ig of a polyclonal anti-VEGF antibody were
mixed with 1 mg of protein extract. The complex was precipitated with
protein-A sepharose, heated at 950C, and the supernatants, containing the
total immunoprecipitated VEGF, were loaded on a 13% gel. After transfer to
an Immobilon-P membrane, the Western blots were probed with either a
polyclonal anti-human NOS2 antibody or with a polyclonal anti-VEGF
antibody
et al, 1995; Larcher et al, 1996; Mazure et al, 1996) and p53
(Kieser et al, 1994) act synergistically with hypoxia to induce
VEGF expression. Furthermore, wild-type p53 regulates NOS2
promoter activity (Forrester et al, 1996), and NOS expression has
been associated with the progression of gynecological and breast
cancers (Thomsen et al, 1994; Thomsen et al, 1995). These obser-
vations suggest that oncogenes and tumour suppressors may
modulate angiogenesis, possibly by regulating VEGF and NOS
expression.
We investigated VEGF and NOS expression in 27 NSCLC.
VEGF was expressed in 50% of the SCC and carcinoids, as
demonstrated by IHC analysis. We did not detect VEGF protein in
six adenocarcinomas, although it has been reported (Mattern et al,
1995). We found that Ca2+-dependent NOS activity, consistent
with neuronal and/or endothelial NOS, was significantly reduced
in tumours compared with adjacent normal lung tissue. The pres-
ence of both isoforms has been demonstrated in nerve elements
and large-vessel endothelial cells in normal human lung (Kobzik et
al, 1993). Reduced tumour vascularity may have caused the
decrease in Ca2+-dependent NOS activity. Three SCC had focally
intense NOS2 expression in tumour-infiltrating monocytes, and
endothelial cells lining larger vessels were labelled in two
tumours. Only one SSC had a small focus of tumour cells that
stained for NOS2. The expression of NOS2 in three SCCs may
have been caused by circulating cytokines (Forstermann and
Kleinert, 1995), perhaps in synergy with hypoxia (Melillo et al,
1995). The regions ofNOS2 expression did not overlap with areas
of VEGF expression, which suggests that NOS2 and VEGF are
induced by different stimuli. Constitutive NOS2 expression was
shown recently in the mucosa of non-inflamed human bronchus
(Guo et al, 1995). We could not detect the Ca2+-independent
activity of NOS2 in most extracts from normal lungs nor did we
find evidence by immunohistochemical staining. Our results indi-
cate that constitutive NOS2 expression is not abundant in normal
human lung and may be restricted to bronchial mucosa in the
proximal airways that were not examined in our study.
p53 mutations occur in 56% ofNSCLC (Greenblatt et al, 1994),
and one-third of adenocarcinomas have K-ras mutations
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(Rodenhuis et al, 1992). Mutations in both genes, specifically the
excess of guanine to thymine transversions observed in lung
cancers, have been linked to tobacco smoking (Takahashi et al,
1991; Rodenhuis et al, 1992). We found p53 mutations in 52% of
our lung cancers and K-ras mutations in 33% of the adenocarci-
nomas. The predominance of guanine to thymine transversions
that account for 36% of p53 mutations and all of the three K-ras
mutations is consistent with the high rate of smoking in our series.
We did not find a correlation between VEGF expression, K-ras
mutation or p53 alteration (i.e. either mutation or protein over-
expression). The rates of K-ras mutation and p53 alteration were
75% in VEGF-positive SCCs and 88% in VEGF-negative SCCs.
The low rates ofboth mutation and VEGF expression among non-
SCC tumours precluded inferences of association. These results
contrast with a recent report that found a statistically significant
association between p53 and VEGF by IHC (Fontanini et al,
1997a). The most notable difference between the series was the
95% rate of VEGF expression reported by Fontanini and co-
workers vs the 50% in SCCs in our cohort vs 59% in SCC in a
third report (Mattern et al, 1995). The discrepancy might be
explained by methodological differences, including the use of
different anti-VEGF antibodies and by cohort differences; the
Fontanini series had more metastatic tumours than ours. The poly-
clonal anti-VEGF antibody (A-20) we used to detect VEGF in
NSCLC was recently published in two colon cancer series
(Takahashi et al, 1995; Kang et al, 1997). We also tested another
polyclonal anti-VEGF antibody that was applied recently to
analyse NSCLCs (Fontanini et al, 1997a). Our experiments
suggested that the A-20 antibody is more specific for immuno-
chemistry. Finally, we observed that detection of VEGF protein
with the A-20 antibody correlates with VEGF mRNA expression
in human carcinoma cells in cell culture (data not shown).
In summary, we found that up-regulation of NOS isoforms is not
associated with progression of NSCLC, as has been suggested for
gynaecological and breast cancers (Thomsen et al, 1994, 1995).
VEGF was expressed in 50% of SCC, however we found no
correlation with p53 and K-ras alterations. Although oncogene and
tumour-suppressor regulation of angiogenesis is an attractive model
for carcinogenesis, these data do not link p53 and K-ras mutations
with increased expression of VEGF or NOS isoforms in NSCLC.
ABBREVIATIONS
VEGF, vascular endothelial growth factor; NO, nitric oxide; NOS,
nitric oxide synthase; SCC, squamous cell carcinoma; NSCLC,
non-small-cell lung cancer; IHC, immunohistochemistry; L-
NMA, L-NG-monomethyl-L-arginine; EGTA, ethylene glycol bis-
(f-aminoethyl ether)-N,N'-tetraacetic acid
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